APE-1/Ref-1 Inhibition Blocks Malignant Pleural Mesothelioma Cell Proliferation and Migration: Crosstalk between Oxidative Stress and Epithelial Mesenchymal Transition (EMT) in Driving Carcinogenesis and Metastasis.
asbestos
epithelial mesenchymal transition
malignant pleural mesothelioma
oxidative stress
proliferation
redox-sensitive factors
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
08 Aug 2023
08 Aug 2023
Historique:
received:
29
06
2023
revised:
01
08
2023
accepted:
07
08
2023
medline:
28
8
2023
pubmed:
26
8
2023
entrez:
26
8
2023
Statut:
epublish
Résumé
Malignant pleural mesothelioma (MPM) is an aggressive cancer associated with asbestos exposure. MPM pathogenesis has been related both to oxidative stress, evoked by and in response to asbestos fibers exposure, and epithelial mesenchymal transition (EMT), an event induced by oxidative stress itself and related to cancer proliferation and metastasis. Asbestos-related primary oxidative damage is counteracted in the lungs by various redox-sensitive factors, often hyperactivated in some cancers. Among these redox-sensitive factors, Apurinic-apyrimidinic endonuclease 1 (APE-1)/Redox effector factor 1 (Ref-1) has been demonstrated to be overexpressed in MPM and lung cancer, but the molecular mechanism has not yet been fully understood. Moreover, asbestos exposure has been associated with induced EMT events, via some EMT transcription factors, such as Twist, Zeb-1 and Snail-1, in possible crosstalk with oxidative stress and inflammation events. To demonstrate this hypothesis, we inhibited/silenced Ref-1 in MPM cells; as a consequence, both EMT (Twist, Zeb-1 and Snail-1) markers and cellular migration/proliferation were significantly inhibited. Taken as a whole, these results show, for the first time, crosstalk between oxidative stress and EMT in MPM carcinogenesis and invasiveness, thus improving the knowledge to better address a preventive and therapeutic approach against this aggressive cancer.
Identifiants
pubmed: 37628748
pii: ijms241612570
doi: 10.3390/ijms241612570
pmc: PMC10454819
pii:
doi:
Substances chimiques
Endonucleases
EC 3.1.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : University of Turin
ID : ALDE_RILO_19_01
Références
Mol Med Rep. 2014 Aug;10(2):1089-95
pubmed: 24890460
Cancer Med. 2018 Sep;7(9):4406-4419
pubmed: 30109782
J Dermatol Sci. 2020 Oct;100(1):67-74
pubmed: 32951990
APMIS. 2013 Jan;121(1):1-10
pubmed: 23030626
Med Oncol. 2017 Mar;34(3):45
pubmed: 28197929
Drug Discov Today. 2021 Jan;26(1):218-228
pubmed: 33148489
Nat Rev Mol Cell Biol. 2019 Feb;20(2):69-84
pubmed: 30459476
Int J Mol Sci. 2019 Jan 03;20(1):
pubmed: 30609805
J Oral Maxillofac Surg. 2019 Apr;77(4):859-866
pubmed: 30611690
Cancer Gene Ther. 2008 Oct;15(10):625-35
pubmed: 18535621
Asian Pac J Cancer Prev. 2013;14(6):3625-30
pubmed: 23886156
Free Radic Biol Med. 2012 Mar 15;52(6):1024-32
pubmed: 22240154
Transl Res. 2009 Apr;153(4):143-52
pubmed: 19304273
Gen Thorac Cardiovasc Surg. 2021 May;69(5):781-789
pubmed: 33754237
Mol Cancer Ther. 2004 Jun;3(6):679-86
pubmed: 15210853
Cancers (Basel). 2021 Mar 07;13(5):
pubmed: 33799965
Cancer Metastasis Rev. 2016 Dec;35(4):645-654
pubmed: 27878502
Cancer Metastasis Rev. 2015 Jun;34(2):229-41
pubmed: 25939322
Oncology. 2014;86(2):109-16
pubmed: 24457449
Eur J Cardiothorac Surg. 2010 Mar;37(3):566-72
pubmed: 19781955
Eur Respir Rev. 2016 Dec;25(142):472-486
pubmed: 27903668
Free Radic Biol Med. 2015 Sep;86:166-78
pubmed: 25975982
Nat Rev Cancer. 2022 May;22(5):280-297
pubmed: 35102280
Transl Lung Cancer Res. 2020 Jun;9(3):924-933
pubmed: 32676358
NPJ Precis Oncol. 2017;1:
pubmed: 28825044
Cancers (Basel). 2017 Aug 03;9(8):
pubmed: 28771186
Front Oncol. 2020 Jan 24;9:1519
pubmed: 32039010
J Exp Clin Cancer Res. 2021 Aug 10;40(1):251
pubmed: 34376225
Mol Cancer Ther. 2019 Nov;18(11):1947-1960
pubmed: 31413178
Int J Oncol. 2014 May;44(5):1643-51
pubmed: 24573038
Antioxid Redox Signal. 2010 Jun 15;12(12):1383-430
pubmed: 19903090
Clin Lymphoma Myeloma. 2007 Jan;7(4):296-304
pubmed: 17324338
J Thorac Dis. 2010 Sep;2(3):154-9
pubmed: 22263037
Mod Pathol. 2012 Jan;25(1):86-99
pubmed: 21983934
Sci Rep. 2022 Jan 19;12(1):1007
pubmed: 35046456
Int J Mol Sci. 2021 Nov 11;22(22):
pubmed: 34830097
Lung Cancer. 2009 Dec;66(3):298-304
pubmed: 19324449